Earnings Scheduled For May 3, 2022
Companies Reporting Before The Bell
• Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.
Deutsche Bank Maintains Hold on Lear, Lowers Price Target to $157
Deutsche Bank analyst Emmanuel Rosner maintains Lear (NYSE:LEA) with a Hold and lowers the price target from $197 to $157.
Expert Ratings for Lear
Lear (NYSE:LEA) has observed the following analyst ratings within the last quarter:
Exane BNP Paribas Initiates Coverage On Lear with Underperform Rating
Exane BNP Paribas initiates coverage on Lear (NYSE:LEA) with a Underperform rating.
Barclays Maintains Equal-Weight on Lear, Lowers Price Target to $132
Barclays maintains Lear (NYSE:LEA) with a Equal-Weight and lowers the price target from $161 to $132.
Morgan Stanley Maintains Equal-Weight on Lear, Lowers Price Target to $160
Morgan Stanley analyst Adam Jonas maintains Lear (NYSE:LEA) with a Equal-Weight and lowers the price target from $175 to $160.
Wells Fargo Maintains Equal-Weight on Lear, Lowers Price Target to $158
Wells Fargo analyst Colin Langan maintains Lear (NYSE:LEA) with a Equal-Weight and lowers the price target from $174 to $158.
